GlassScriptPhysician profile
Christopher G Lamb
NPI 1093226938
$4,850.14
in general payments reported to CMS, 2019-2025
26 companies · $2,594 in 2025
The $2,594 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $224 · 2022: $657 · 2023: $390 · 2024: $985 · 2025: $2,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254 · Travel and Lodging: $1,253 · Education: $312 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,253.63 |
| Travel and Lodging | $1,253.01 |
| Education | $312.23 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,547.01 | 2022-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $775.64 | 2021-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $573.84 | 2021-2025 | Breztri, Tezspire, Fasenra |
| United Therapeutics Corporation | $200.00 | 2022-2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $199.86 | 2024-2025 | Winrevair |
| Abiomed | $191.58 | 2024 | Impella |
| Harmony Biosciences LLC | $170.57 | 2023-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $150.00 | 2025 | |
| Axsome Therapeutics, INC. | $137.61 | 2024-2025 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $115.77 | 2024-2025 | Glassia |
| Insmed, INC. | $108.15 | 2021-2025 | Brinsupri, Arikayce |
| Regeneron Healthcare Solutions, INC. | $99.26 | 2025 | Dupixent |
| Philips North America LLC | $98.46 | 2024-2025 | Patient Interface Software, (8874) Incourage |
| Glaxosmithkline, LLC. | $95.13 | 2023-2025 | Nucala, Trelegy Ellipta |
| Grifols USA, LLC | $76.46 | 2024-2025 | Prolastin-C Liquid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $73.88 | 2023 | |
| Verona Pharma, INC. | $56.71 | 2025 | Ohtuvayre |
| Cvrx, INC. | $26.06 | 2024 | Barostim Neo System |
| Avadel Cns Pharmaceuticals, LLC | $24.27 | 2025 | Lumryz |
| Inogen, INC. | $23.90 | 2022-2024 | |
| Baxter Healthcare | $23.79 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Bayer Healthcare Pharmaceuticals INC. | $21.52 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.40 | 2025 | Jascayd |
| Pulmonx Corporation | $14.73 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Mylan Specialty L.P. | $14.43 | 2023 | Yupelri |
| Resmed Corp | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.